T Cell Immunity and Zika Virus Vaccine Development

Trends in Immunology

Volumn 38, Issue 8, 2017, Pages 594-605

  Lima, Noemia S ^a,b   Rolland, Morgane ^a,b   Modjarrad, Kayvon ^a,b   Trautmann, Lydie ^a,b  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ZIKA VIRUS VACCINE; VIRUS VACCINE;

CELL SPECIFICITY; CELLULAR IMMUNITY; CROSS REACTION; HUMAN; NONHUMAN; REVIEW; VACCINATION; VIRUS IMMUNITY; ZIKA FEVER; ANIMAL; DENGUE VIRUS; HETEROLOGOUS IMMUNITY; IMMUNOLOGY; T LYMPHOCYTE; VIROLOGY; ZIKA VIRUS;

ANIMALS; DENGUE VIRUS; HUMANS; IMMUNITY, HETEROLOGOUS; T-LYMPHOCYTES; VIRAL VACCINES; ZIKA VIRUS; ZIKA VIRUS INFECTION;

EID: 85020104454     PISSN: 14714906     EISSN: 14714981     Source Type: Journal    
DOI: 10.1016/j.it.2017.05.004     Document Type: Review

References (112)

1. Musso, D., Gubler, D.J., Zika virus. Clin. Microbiol. Rev. 29 (2016), 487–524.
2. Petersen, L.R., et al. Zika virus. N. Engl. J. Med. 374 (2016), 1552–1563.
3. Fauci, A.S., Morens, D.M., Zika virus in the Americas – yet another arbovirus threat. N. Engl. J. Med. 374 (2016), 601–604.
4. Grischott, F., et al. Non-vector-borne transmission of Zika virus: a systematic review. Travel Med. Infect. Dis. 14 (2016), 313–330.
5. D'Ortenzio, E., et al. Evidence of sexual transmission of Zika virus. N. Engl. J. Med. 374 (2016), 2195–2198.
6. Dudley, D.M., et al. A rhesus macaque model of Asian-lineage Zika virus infection. Nat. Commun., 7, 2016, 12204.
7. Osuna, C.E., et al. Zika viral dynamics and shedding in rhesus and cynomolgus macaques. Nat. Med. 22 (2016), 1448–1455.
8. Bonaldo, M.C., et al. Isolation of infective Zika virus from urine and saliva of patients in Brazil. PLoS Negl. Trop. Dis., 10, 2016, e0004816.
9. Paz-Bailey, G., et al. 2017 Persistence of Zika virus in body fluids – preliminary report. N. Engl. J. Med., 2017, 10.1056/NEJMoa1613108 Published online February 14, 2017.
10. Sotelo, J.R., et al. Persistence of Zika virus in breast milk after infection in late stage of pregnancy. Emerg. Infect. Dis. 23 (2017), 856–857.
11. Aid, M., et al. Zika virus persistence in the central nervous system and lymph nodes of rhesus monkeys. Cell 169 (2017), 610–620.
12. Pierson, T.C., Graham, B.S., Zika virus: immunity and vaccine development. Cell 167 (2016), 625–631.
13. Lazear, H.M., Diamond, M.S., Zika virus: new clinical syndromes and its emergence in the Western Hemisphere. J. Virol. 90 (2016), 4864–4875.
14. Brasil, P., et al. Zika virus infection in pregnant women in Rio de Janeiro. N. Engl. J. Med. 375 (2016), 2321–2334.
15. Brasil, P., et al. Guillain–Barre syndrome associated with Zika virus infection. Lancet, 387, 2016, 1482.
16. Carteaux, G., et al. Zika virus associated with meningoencephalitis. N. Engl. J. Med. 374 (2016), 1595–1596.
17. Mecharles, S., et al. Acute myelitis due to Zika virus infection. Lancet, 387, 2016, 1481.
18. Mlakar, J., et al. Zika virus associated with microcephaly. N. Engl. J. Med. 374 (2016), 951–958.
19. Gulland, A., Zika virus is a global public health emergency, declares WHO. Br. Med. J., 352, 2016, i657.
20. Ishikawa, T., et al. A review of successful flavivirus vaccines and the problems with those flaviviruses for which vaccines are not yet available. Vaccine 32 (2014), 1326–1337.
21. Srikiatkhachorn, A., Yoon, I.K., Immune correlates for dengue vaccine development. Expert Rev. Vaccines 15 (2016), 455–465.
22. Barouch, D.H., et al. Prospects for a Zika virus vaccine. Immunity 46 (2017), 176–182.
23. Turtle, L., et al. Human T cell responses to Japanese encephalitis virus in health and disease. J. Exp. Med. 213 (2016), 1331–1352.
24. + T cell responses to an inactivated flavivirus vaccine and infection: correlation with structure and epitope prediction. J. Virol. 88 (2014), 7828–7842.
25. Pulendran, B., Learning immunology from the yellow fever vaccine: innate immunity to systems vaccinology. Nat. Rev. Immunol. 9 (2009), 741–747.
26. Muyanja, E., et al. Immune activation alters cellular and humoral responses to yellow fever 17D vaccine. J. Clin. Invest. 124 (2014), 3147–3158.
27. Rothman, A.L., et al. Analysis of cell-mediated immune responses in support of dengue vaccine development efforts. Vaccine 33 (2015), 7083–7090.
28. + T cells. J. Immunol. 182 (2009), 4865–4873.
29. + T cells complement antibodies in protecting against yellow fever virus. J. Immunol. 194 (2015), 1141–1153.
30. Mathews, J.H., et al. A synthetic peptide to the E glycoprotein of Murray Valley encephalitis virus defines multiple virus-reactive T- and B-cell epitopes. J. Virol. 66 (1992), 6555–6562.
31. Hughes, H.R., et al. A West Nile virus CD4 T cell epitope improves the immunogenicity of dengue virus serotype 2 vaccines. Virology 424 (2012), 129–137.
32. + T cells to recovery from infection in a murine model of Japanese encephalitis. J. Virol. 85 (2011), 5446–5555.
33. Zellweger, R.M., et al. Role of humoral versus cellular responses induced by a protective dengue vaccine candidate. PLoS Pathog., 9, 2013, e1003723.
34. + T-cell responses are required for clearance of West Nile virus from the central nervous system. J. Virol. 80 (2006), 12060–12069.
35. + T cell or antibody responses but contribute to protection after vaccination. J. Immunol. 185 (2010), 5405–5416.
36. Mathew, A., et al. Elucidating the role of T cells in protection against and pathogenesis of dengue virus infections. Future Microbiol. 9 (2014), 411–425.
37. + T cells associated with protective immunity. Proc. Natl. Acad. Sci. U. S. A. 112 (2015), E4256–E4263.
38. + T cell epitope in immunocompetent mice. PLoS Pathog., 13, 2017, e1006184.
39. Stettler, K., et al. Specificity, cross-reactivity and function of antibodies elicited by Zika virus infection. Science 353 (2016), 823–826.
40. + T cells in control of West Nile virus infection. J. Virol. 78 (2004), 8312–8321.
41. Prestwood, T.R., et al. Gamma interferon (IFN-gamma) receptor restricts systemic dengue virus replication and prevents paralysis in IFN-alpha/beta receptor-deficient mice. J. Virol. 86 (2012), 12561–12570.
42. Tang, H., et al. Zika virus infects human cortical neural progenitors and attenuates their growth. Cell Stem Cell 18 (2016), 587–590.
43. + T cell immunity to dengue – lessons for the study of Zika virus. Immunology 150 (2017), 146–154.
44. Cugola, F.R., et al. The Brazilian Zika virus strain causes birth defects in experimental models. Nature 534 (2016), 267–271.
45. + T cell response during primary Zika virus infection in mice. Cell Host Microbe 21 (2017), 35–46.
46. Hickman, H.D., Pierson, T.C., T cells take on Zika virus. Immunity 46 (2017), 13–14.
47. + T cells. Nat. Microbiol., 2, 2017, 17036.
48. Winkler, C.W., et al. Adaptive immune responses to Zika virus are important for controlling virus infection and preventing infection in brain and testes. J. Immunol. 198 (2017), 3526–3535.
49. + T cells prevent antigen-induced antibody-dependent enhancement of dengue disease in mice. J. Immunol. 193 (2014), 4117–4124.
50. Screaton, G., et al. New insights into the immunopathology and control of dengue virus infection. Nat. Rev. Immunol. 15 (2015), 745–759.
51. Rothman, A.L., et al. Immunopathogenesis versus protection in Dengue virus infections. Curr. Trop. Med. Rep. 1 (2014), 13–20.
52. + T cells. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), E2046–E2053.
53. Zivna, I., et al. T cell responses to an HLA-B*07-restricted epitope on the dengue NS3 protein correlate with disease severity. J. Immunol. 168 (2002), 5959–5965.
54. Duangchinda, T., et al. Immunodominant T-cell responses to dengue virus NS3 are associated with DHF. Proc. Natl. Acad. Sci. U. S. A. 107 (2010), 16922–16927.
55. Mongkolsapaya, J., et al. Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. Nat. Med. 9 (2003), 921–927.
56. Friberg, H., et al. Cross-reactivity and expansion of dengue-specific T cells during acute primary and secondary infections in humans. Sci. Rep., 1, 2011, 51.
57. Ritter, J.M., et al. Zika virus: pathology from the pandemic. Arch. Pathol. Lab. Med. 141 (2016), 49–59.
58. Cao-Lormeau, V.M., et al. Guillain-Barre syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. Lancet 387 (2016), 1531–1539.
59. Oehler, E., et al. Zika virus infection complicated by Guillain-Barre syndrome–case report, French Polynesia, December 2013. Euro Surveill, 19, 2014, 20720.
60. Lucchese, G., Kanduc, D., Zika virus and autoimmunity: from microcephaly to Guillain-Barre syndrome, and beyond. Autoimmun. Rev. 15 (2016), 801–808.
61. Ye, Q., et al. Genomic characterization and phylogenetic analysis of Zika virus circulating in the Americas. Infect. Genet. Evol. 43 (2016), 43–49.
62. Dowd, K.A., et al. Broadly neutralizing activity of Zika virus-immune sera identifies a single viral serotype. Cell Rep. 16 (2016), 1485–1491.
63. Haddow, A.D., et al. Genetic characterization of Zika virus strains: geographic expansion of the Asian lineage. PLoS Negl. Trop. Dis., 6, 2012, e1477.
64. Xu, X., et al. Identifying candidate targets of immune responses in Zika virus based on homology to epitopes in other flavivirus species. PLoS Curr., 8, 2016 ecurrents.outbreaks.9aa2e1fb61b0f632f58a098773008c4b.
65. Sumathy, K., et al. Protective efficacy of Zika vaccine in AG129 mouse model. Sci. Rep., 7, 2017, 46375.
66. Robbiani, D.F., et al. Recurrent potent human neutralizing antibodies to Zika virus in Brazil and Mexico. Cell 169 (2017), 597–609.
67. Dejnirattisai, W., et al. Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus. Nat. Immunol. 17 (2016), 1102–1108.
68. Bardina, S.V., et al. Enhancement of Zika virus pathogenesis by preexisting antiflavivirus immunity. Science 356 (2017), 175–180.
69. + T lymphocytes in dengue virus infection. J. Virol. 87 (2013), 2693–2706.
70. Kaabinejadian, S., et al. Identification of class I HLA T cell control epitopes for West Nile virus. PLoS One, 8, 2013, e66298.
71. Vaughan, K., et al. Meta-analysis of all immune epitope data in the Flavivirus genus: inventory of current immune epitope data status in the context of virus immunity and immunopathology. Viral Immunol. 23 (2010), 259–284.
72. Weiskopf, D., et al. Insights into HLA-restricted T cell responses in a novel mouse model of dengue virus infection point toward new implications for vaccine design. J. Immunol. 187 (2011), 4268–4279.
73. + T-cell responses against the 4 dengue virus serotypes are associated with distinct patterns of protein targets. J. Infect. Dis. 212 (2015), 1743–1751.
74. + T cell responses to an attenuated tetravalent dengue vaccine parallel those induced by natural infection in magnitude, HLA restriction, and antigen specificity. J. Virol., 91, 2017 e02147–e02116.
75. Weiskopf, D., et al. Immunodominance changes as a function of the infecting dengue virus serotype and primary versus secondary infection. J. Virol. 88 (2014), 11383–11394.
76. + T cells can mediate short-term protection against heterotypic dengue virus reinfection in mice. J. Virol. 89 (2015), 6494–6505.
77. Li, J., et al. Cross-protection induced by Japanese encephalitis vaccines against different genotypes of dengue viruses in mice. Sci. Rep., 6, 2016, 19953.
78. McCracken, M.K., et al. Zika virus infection in rhesus macaques is not altered by prior immunity to related flaviviruses. PLoS Pathog., 13, 2017, e1006219.
79. Thomas, S.J., et al. Fast-track Zika vaccine development – is it possible?. N. Engl. J. Med. 375 (2016), 1212–1216.
80. Olagnier, D., et al. Dengue virus immunopathogenesis: lessons applicable to the emergence of Zika virus. J. Mol. Biol. 428 (2016), 3429–3448.
81. Barrett, A.D., Teuwen, D.E., Yellow fever vaccine – how does it work and why do rare cases of serious adverse events take place?. Curr. Opin. Immunol. 21 (2009), 308–313.
82. Barba-Spaeth, G., et al. Live attenuated yellow fever 17D infects human DCs and allows for presentation of endogenous and recombinant T cell epitopes. J. Exp. Med. 202 (2005), 1179–1184.
83. + T cell response. J. Immunol. 183 (2009), 7919–7930.
84. + T cell responses that recognize structural and nonstructural proteins. J. Virol. 87 (2013), 12794–12804.
85. Querec, T., et al. Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J. Exp. Med. 203 (2006), 413–424.
86. Gaucher, D., et al. Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. J. Exp. Med. 205 (2008), 3119–3131.
87. Blom, K., et al. Temporal dynamics of the primary human T cell response to yellow fever virus 17D as it matures from an effector- to a memory-type response. J. Immunol. 190 (2013), 2150–2158.
88. Kohler, S., et al. The early cellular signatures of protective immunity induced by live viral vaccination. Eur. J. Immunol. 42 (2012), 2363–2373.
89. Akondy, R.S., et al. Initial viral load determines the magnitude of the human CD8 T cell response to yellow fever vaccination. Proc. Natl. Acad. Sci. U. S. A. 112 (2015), 3050–3055.
90. + T cell responses to smallpox and yellow fever vaccines. Immunity 28 (2008), 710–722.
91. Rivino, L., et al. Virus-specific T lymphocytes home to the skin during natural dengue infection. Sci. Transl. Med., 7, 2015, 278ra35.
92. + phenotype. J. Virol. 90 (2016), 4771–4779.
93. Guy, B., et al. Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. Vaccine 28 (2010), 632–649.
94. Harenberg, A., et al. Persistence of Th1/Tc1 responses one year after tetravalent dengue vaccination in adults and adolescents in Singapore. Hum. Vaccin. Immunother. 9 (2013), 2317–2325.
95. Guy, B., Jackson, N., Dengue vaccine: hypotheses to understand CYD-TDV-induced protection. Nat. Rev. Microbiol. 14 (2016), 45–54.
96. Ferguson, N.M., et al. Benefits and risks of the Sanofi-Pasteur dengue vaccine: modeling optimal deployment. Science 353 (2016), 1033–1036.
97. Guy, B., et al. Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects. Vaccine 26 (2008), 5712–5721.
98. Weiskopf, D., Sette, A., T-cell immunity to infection with dengue virus in humans. Front. Immunol., 5, 2014, 93.
99. Guy, B., et al. From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine. Vaccine 29 (2011), 7229–7241.
100. + T cell responses. J. Infect. Dis. 202 (2010), 223–233.
101. + T cell responses induced by a live attenuated tetravalent dengue vaccine are directed against highly conserved epitopes. J. Virol. 89 (2015), 120–128.
102. Simmons, M., et al. Recombinant dengue 2 virus NS3 helicase protein enhances antibody and T-cell response of purified inactivated vaccine. PLoS One, 11, 2016, e0152811.
103. Marston, H.D., et al. Considerations for developing a Zika virus vaccine. N. Engl. J. Med. 375 (2016), 1209–1212.
104. Dowd, K.A., et al. Rapid development of a DNA vaccine for Zika virus. Science 354 (2016), 237–240.
105. Richner, J.M., et al. Modified mRNA vaccines protect against Zika virus infection. Cell 168 (2017), 1114–1125.
106. Abbink, P., et al. Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys. Science 353 (2016), 1129–1132.
107. Larocca, R.A., et al. Vaccine protection against Zika virus from Brazil. Nature 536 (2016), 474–478.
108. Shan, C., et al. A live-attenuated Zika virus vaccine candidate induces sterilizing immunity in mouse models. Nat. Med., 2017, 10.1038/nm.4322 Published online April 10, 2017.
109. Fernandez, E., Diamond, M.S., Vaccination strategies against Zika virus. Curr. Opin. Virol. 23 (2017), 59–67.
110. Rothman, A.L., Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms. Nat. Rev. Immunol. 11 (2011), 532–543.
111. + T cells to heterologous serotypes. J. Immunol. 175 (2005), 2676–2683.
112. + T cells display quantitative and qualitative differences in their response to variant epitopes of heterologous viral serotypes. J. Immunol. 176 (2006), 2817–2824.